renal magnesium wasting
Recently Published Documents


TOTAL DOCUMENTS

47
(FIVE YEARS 0)

H-INDEX

19
(FIVE YEARS 0)

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Howard J. Li ◽  
Catherine Groden ◽  
Melanie P. Hoenig ◽  
Evan C. Ray ◽  
Carlos R. Ferreira ◽  
...  

Abstract Background 17q12 deletion syndrome encompasses a broad constellation of clinical phenotypes, including renal magnesium wasting, maturity-onset diabetes of the young (MODY), renal cysts, genitourinary malformations, and neuropsychiatric illness. Manifestations outside of the renal, endocrine, and nervous systems have not been well described. Case presentation We report a 62-year-old male referred to the Undiagnosed Diseases Program (UDP) at the National Institutes of Health (NIH) who presented with persistent hypermagnesiuric hypomagnesemia and was found to have a 17q12 deletion. The patient exhibited several known manifestations of the syndrome, including severe hypomagnesemia, renal cysts, diabetes and cognitive deficits. Coronary CT revealed extensive coronary calcifications, with a coronary artery calcification score of 12,427. Vascular calcifications have not been previously reported in this condition. We describe several physiologic mechanisms and a review of literature to support the expansion of the 17q12 deletion syndrome to include vascular calcification. Conclusion Extensive coronary and vascular calcifications may be an extension of the 17q12 deletion phenotype, particularly if hypomagnesemia and hyperparathyroidism are prevalent. In patients with 17q12 deletions involving HNF1B, hyperparathyroidism and hypomagnesemia may contribute to significant cardiovascular risk.


2019 ◽  
Vol 73 (2) ◽  
pp. 288-290
Author(s):  
Anneke P. Bech ◽  
Jack F.M. Wetzels ◽  
Hans Groenewoud ◽  
Tom Nijenhuis

2019 ◽  
Vol 9 (5) ◽  
pp. 316-325 ◽  
Author(s):  
Dana V. Rizk ◽  
Arnold L. Silva ◽  
Pablo E. Pergola ◽  
Robert Toto ◽  
David G. Warnock ◽  
...  

Background: Treatment with bardoxolone methyl (Bard) in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate with concurrent reductions in serum magnesium. We analyzed data from several trials to characterize reductions in magnesium with Bard. Methods: BEACON randomized patients (n = 2,185) with type 2 diabetes (T2DM) and stage 4 chronic kidney disease (CKD) 1:1 to receive Bard (20 mg) or placebo once daily. In a separate open-label study, magnesium levels from 24-hour urine and sublingual epithelial cell samples were analyzed in patients with stage 3b-4 CKD and T2DM administered 20 mg Bard for 56 consecutive days. Results: BEACON patients randomized to Bard experienced significant reductions in serum magnesium from baseline relative to patients randomized to placebo (–0.17 mEq/L, 95% CI –0.18 to –0.60 mEq/L; p < 0.001). A separate study showed intracellular and urinary magnesium levels were unchanged with Bard treatment. Conclusions: Bard treatment results in significant decreases in serum magnesium that are not associated with changes in intracellular and urinary magnesium levels, indicating that magnesium decreases are not due to renal magnesium wasting or total body magnesium depletion. Importantly, the decreases in serum magnesium with Bard are not associated with adverse effects on QT interval.


2016 ◽  
Vol 4 (8) ◽  
pp. e12773
Author(s):  
Christopher M. Stark ◽  
Cade M. Nylund ◽  
Gregory H. Gorman ◽  
Brent L. Lechner

2015 ◽  
Vol 42 (1) ◽  
pp. 85-90 ◽  
Author(s):  
Cas I. van der Made ◽  
Ewout J. Hoorn ◽  
Renaud de la Faille ◽  
Huseyin Karaaslan ◽  
Nine V.A.M. Knoers ◽  
...  

Background: Autosomal dominant tubulointerstitial kidney disease subtype HNF1B (ADTKD-HNF1B) is caused by a mutation in hepatocyte nuclear factor 1 homeobox beta (HNF1B). Although 50-60% of ADTKD-HNF1B patients develop hypomagnesemia, HNF1B mutations are mainly identified in patients with structural kidney defects or diabetes. Cases: The current case series describes 3 patients in whom hypomagnesemia proved to be the first clinical manifestation of ADTKD-HNF1B. All patients presented with hypomagnesemia with a high fractional excretion of Mg2+ and hypocalciuria. Exome sequencing performed for analysis of known and candidate hypomagnesaemia genes and subsequent multiplex ligation-dependent probe amplification analysis revealed a large deletion at the chromosome 17q12. Follow-up analysis showed increased blood glucose concentrations in all 3 patients and high hemoglobin A1c levels in 2 out of 3 patients, indicating diabetes mellitus. Although all patients suffered from mild renal insufficiency, only 1 of the 3 patients was shown to have renal cysts on CT. Conclusion: The prevalence of HNF1B mutations and the relative contribution of hypomagnesemia to its symptoms are underestimated. Therefore, patients with primary renal magnesium wasting should be tested for HNF1B mutations to ensure early detection and optimal management of ADTKD-HNF1B.


2013 ◽  
Vol 25 (3) ◽  
pp. 574-586 ◽  
Author(s):  
Silvia Ferrè ◽  
Jeroen H.F. de Baaij ◽  
Patrick Ferreira ◽  
Roger Germann ◽  
Johannis B.C. de Klerk ◽  
...  

2009 ◽  
Vol 20 (5) ◽  
pp. 1123-1131 ◽  
Author(s):  
Shazia Adalat ◽  
Adrian S. Woolf ◽  
Karen A. Johnstone ◽  
Andrea Wirsing ◽  
Lorna W. Harries ◽  
...  

2007 ◽  
Vol 23 (3) ◽  
pp. 952-958 ◽  
Author(s):  
S. Khositseth ◽  
N. Sudjaritjan ◽  
P. Tananchai ◽  
S. Ong-ajyuth ◽  
V. Sitprija ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document